The stock of Novabay Pharmaceuticals Inc (AMEX: NBY) has increased by 4.98 when compared to last closing price of 0.54. Despite this, the company has experienced a 15.67% gain in its stock price over the last five trading sessions. zacks.com reported 2024-12-25 that NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in Novabay Pharmaceuticals Inc (AMEX: NBY) Right Now?
Moreover, the 36-month beta value for NBY is 0.67. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBY is 4.89M and currently, short sellers hold a 0.78% of that float. On December 27, 2024, NBY’s average trading volume was 455.58K shares.
NBY’s Market Performance
NBY’s stock has seen a 15.67% increase for the week, with a -8.87% drop in the past month and a -22.36% fall in the past quarter. The volatility ratio for the week is 6.88%, and the volatility levels for the past 30 days are at 6.70% for Novabay Pharmaceuticals Inc The simple moving average for the past 20 days is 1.19% for NBY’s stock, with a -68.42% simple moving average for the past 200 days.
Analysts’ Opinion of NBY
Many brokerage firms have already submitted their reports for NBY stocks, with Ladenburg Thalmann repeating the rating for NBY by listing it as a “Buy.” The predicted price for NBY in the upcoming period, according to Ladenburg Thalmann is $1.10 based on the research report published on September 18, 2019 of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NBY reach a price target of $4. The rating they have provided for NBY stocks is “Buy” according to the report published on July 06th, 2018.
Laidlaw gave a rating of “Buy” to NBY, setting the target price at $8 in the report published on November 15th of the previous year.
NBY Trading at -9.60% from the 50-Day Moving Average
After a stumble in the market that brought NBY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.76% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares sank -6.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.62% lower at present.
During the last 5 trading sessions, NBY rose by +15.67%, which changed the moving average for the period of 200-days by -88.21% in comparison to the 20-day moving average, which settled at $0.5601. In addition, Novabay Pharmaceuticals Inc saw -92.06% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NBY
Current profitability levels for the company are sitting at:
- -0.4 for the present operating margin
- 0.61 for the gross margin
The net margin for Novabay Pharmaceuticals Inc stands at -0.9. The total capital return value is set at -2.37. Equity return is now at value -246.52, with -119.49 for asset returns.
Based on Novabay Pharmaceuticals Inc (NBY), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -86.51. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -5.15.
Currently, EBITDA for the company is -4.8 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 0.29. The receivables turnover for the company is 15.91for trailing twelve months and the total asset turnover is 2.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.15.
Conclusion
To wrap up, the performance of Novabay Pharmaceuticals Inc (NBY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
